Competition heats up for insulin biosimilar market, scientist says

Competition heats up for insulin biosimilar market, scientist says

August 6, 2014 – With the EMA’s CHMP recommending approval for a new insulin biosimilar early last month, some in the industry are expecting an increasingly competitive field moving forward. Dr. Marcus Hompesch, President and CEO of ProSciento, Inc., told Biopharma-Reporter.com that the market seems ripe to grow as he’s seeing an uptick in clinical trials around insulin biosimilar.
Read the full article at Biopharma-Reporter.com »